TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy.
Activating CD40 is “a key to initiating a T-cell response to tumors,” says Dr. Robert Vonderheide, MD, director of U Penn’s Abramson Cancer Center.
A retrospective study of ICIs by French investigators found manageable toxicity in patients over age 70, and survival outcomes comparable to younger patients.
In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.
Given disconcerting low success rates overall in immunotherapy, some leading oncologists are calling for greater scientific rigor in clinical trial design.
Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.
In this article, we detail the experience with immune checkpoint inhibitors in patients with autoimmune disease.
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination.
A significant number of patients receiving immune checkpoint inhibitor therapy have developed myocarditis, but the reasons behind it are still unclear.